A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder
A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder
PURPOSE: We conducted a multicenter randomized trial in the United Kingdom to determine the efficacy of radical radiotherapy in reducing the incidence of progression of pT1G3 transitional cell carcinoma of the bladder to muscle invasive disease and subsequent disease fatality.
MATERIALS AND METHODS: Patients with a new diagnosis of pT1G3 NXM0 transitional cell carcinoma with unifocal disease and no carcinoma in situ (group 1), or with multifocal disease and/or carcinoma in situ (group 2) were eligible for the trial. Patients in group 1 were randomized between observation and radiotherapy to the bladder, and in group 2 between intravesical therapy and radiotherapy.
RESULTS: From September 1991 to February 2003 a total of 210 patients from 37 centers in the United Kingdom were entered into the study. There were 77 patients in group 1 and 133 patients in group 2, and 6 patients were excluded from analysis because they were found to have pT2 disease by the reference pathologist. No evidence of an advantage with radiotherapy was found in terms of progression-free interval (hazard ratio 1.07; 95% CI 0.65, 1.74; p = 0.785), progression-free survival (hazard ratio 1.35; 95% CI 0.92, 1.98; p = 0.133) or overall survival (hazard ratio 1.32; 95% CI 0.86, 2.04; p = 0.193).
CONCLUSIONS: To our knowledge this is the largest randomized trial performed in patients with pT1G3 disease for which 210 patients were recruited during 11 years. There is no evidence that radiotherapy is better than more conservative treatment. The prognosis of this group of patients appears to be poor irrespective of treatment and new treatment strategies need to be investigated.
Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Survival Rate, Urinary Bladder Neoplasms, Journal Article, Multicenter Study, Randomized Controlled Trial
807-813
Harland, S.J.
7905b58d-f379-4372-bfce-d86383da8ea9
Kynaston, H.
cc327bde-bf3b-4e32-9bdb-da36c76aa4f9
Grigor, K.
204ae200-cae4-41dd-b254-d125b1868c07
Wallace, D.M.
b1e30db6-3def-4336-bd82-080637a0d4ab
Beacock, C.
318659bb-8e01-404d-9e22-f4e4ceb82bbd
Kockelbergh, R.
74902b46-de9a-4c58-9392-ec834e039d90
Clawson, S.
fe269a62-4b15-4b45-b425-499186c7959b
Barlow, T.
90765474-cd91-441e-ba07-be58059d0951
Parmar, M.K.B.
44634dd0-3f2b-4263-9f16-308a9e9260b8
Griffiths, G.O.
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
National Cancer Research Institute Bladder Clinical Studies Group
September 2007
Harland, S.J.
7905b58d-f379-4372-bfce-d86383da8ea9
Kynaston, H.
cc327bde-bf3b-4e32-9bdb-da36c76aa4f9
Grigor, K.
204ae200-cae4-41dd-b254-d125b1868c07
Wallace, D.M.
b1e30db6-3def-4336-bd82-080637a0d4ab
Beacock, C.
318659bb-8e01-404d-9e22-f4e4ceb82bbd
Kockelbergh, R.
74902b46-de9a-4c58-9392-ec834e039d90
Clawson, S.
fe269a62-4b15-4b45-b425-499186c7959b
Barlow, T.
90765474-cd91-441e-ba07-be58059d0951
Parmar, M.K.B.
44634dd0-3f2b-4263-9f16-308a9e9260b8
Griffiths, G.O.
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Harland, S.J., Kynaston, H., Grigor, K., Wallace, D.M., Beacock, C., Kockelbergh, R., Clawson, S., Barlow, T., Parmar, M.K.B. and Griffiths, G.O.
,
National Cancer Research Institute Bladder Clinical Studies Group
(2007)
A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.
The Journal of Urology, 178 (3), .
(doi:10.1016/j.juro.2007.05.024).
Abstract
PURPOSE: We conducted a multicenter randomized trial in the United Kingdom to determine the efficacy of radical radiotherapy in reducing the incidence of progression of pT1G3 transitional cell carcinoma of the bladder to muscle invasive disease and subsequent disease fatality.
MATERIALS AND METHODS: Patients with a new diagnosis of pT1G3 NXM0 transitional cell carcinoma with unifocal disease and no carcinoma in situ (group 1), or with multifocal disease and/or carcinoma in situ (group 2) were eligible for the trial. Patients in group 1 were randomized between observation and radiotherapy to the bladder, and in group 2 between intravesical therapy and radiotherapy.
RESULTS: From September 1991 to February 2003 a total of 210 patients from 37 centers in the United Kingdom were entered into the study. There were 77 patients in group 1 and 133 patients in group 2, and 6 patients were excluded from analysis because they were found to have pT2 disease by the reference pathologist. No evidence of an advantage with radiotherapy was found in terms of progression-free interval (hazard ratio 1.07; 95% CI 0.65, 1.74; p = 0.785), progression-free survival (hazard ratio 1.35; 95% CI 0.92, 1.98; p = 0.133) or overall survival (hazard ratio 1.32; 95% CI 0.86, 2.04; p = 0.193).
CONCLUSIONS: To our knowledge this is the largest randomized trial performed in patients with pT1G3 disease for which 210 patients were recruited during 11 years. There is no evidence that radiotherapy is better than more conservative treatment. The prognosis of this group of patients appears to be poor irrespective of treatment and new treatment strategies need to be investigated.
This record has no associated files available for download.
More information
Published date: September 2007
Keywords:
Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Survival Rate, Urinary Bladder Neoplasms, Journal Article, Multicenter Study, Randomized Controlled Trial
Organisations:
Clinical Trials Unit
Identifiers
Local EPrints ID: 406331
URI: http://eprints.soton.ac.uk/id/eprint/406331
ISSN: 0022-5347
PURE UUID: a25cda1f-55f8-4454-8a07-a0debf955980
Catalogue record
Date deposited: 10 Mar 2017 10:44
Last modified: 16 Mar 2024 04:19
Export record
Altmetrics
Contributors
Author:
S.J. Harland
Author:
H. Kynaston
Author:
K. Grigor
Author:
D.M. Wallace
Author:
C. Beacock
Author:
R. Kockelbergh
Author:
S. Clawson
Author:
T. Barlow
Author:
M.K.B. Parmar
Corporate Author: National Cancer Research Institute Bladder Clinical Studies Group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics